With IBS affecting 10 to 15% of the global population, the associated $21 billion in direct medical costs and absenteeism underscores the urgent need of innovative solutions. Recognized as the 7th...
IRVINE, Calif., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ: BMRA), a global biomedical company leading the way in innovative gastroenterology solutions, proudly announces the...
Biomerica Reports First Quarter 2024 Financial Results. Revenues excluding Covid test sales increased 16.3% for first fiscal quarter of 2024
Biomerica Reports First Quarter 2024 Financial Results. Revenues excluding Covid test sales increased 16.3% for first fiscal quarter of 2024
Revenues excluding Covid test sales increased 15% for fiscal 2023 vs fiscal 2022 Successfully completed inFoods® IBS pilot program with one of the largest Gastrointestinal physician groups in the US ...
Over 7,000 CVS Pharmacy Stores to sell the EZ Detect„¢ TestSimple 2 minute at-home test detects an early warning sign of colorectal cancer IRVINE, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) --...
Patent Claims Describe a Novel System to Predict and Help Prevent Adverse Food Reactions Using Personal Medical DataThe Patent further describes Algorithms to help Determine Safety Levels of Food...
Gastro Health, a leading gastroenterology group, plans to utilize this simplified blood collection method when recommending the inFoods® IBS to their patients Biomerica also announced that inFoods®...
Biomerica Reports Q3 Fiscal 2023 Results
Biomerica announces the Launch of InFoods IBS as a Laboratory Developed Test (LDT); First patient samples have been processed